Background: Because of a change of government, the Colombian Ministry of Health and Social Protection is in the process of presenting a structural reform for the General System of Social Security in Health (GSSSH), in order to implement a ‘preventive and predictive health model’. However, it will always be relevant to review and analyze the fiscal implications of any proposed public policy program, to protect financial sustainability and to promote the better functioning of the system in question. Methods: To contribute to this topic, we have calculated, using a financial–actuarial approach, the loss ratio for the years 2017 to 2021 for the Capitation Payment Unit (CPU) for all the Health-Promoting Entities (HPE) for both contributory and subsidized schemes. This information, derived from public reports available on the official website of the National Health Superintendency, allows us to estimate the financial burden of the institutions that guarantee access to and provision of health services and technologies in Colombia. Results: The study shows that close to half of the HPEs in Colombia (which represent 11.6 million affiliates) have CPU loss ratios of more than 100% for the year 2021, evidencing insufficient resources for the operation of health insurance. Conclusions: Finally, we propose some policy recommendations regarding the strengthening of informed decision-making to allow the healthy financial sustainability of the Colombian GSSSH.
29 September 2021 in Regional Science Policy & Practice
To mitigate the effects of the COVID-19 pandemic, different countries have developed computational tools and dashboards that allow generating value for decision-making in public health. We aimed to build an interactive geographic viewer for vulnerability to COVID-19 at the block level to identify the location of populations that because of sociodemographic characteristics and health conditions could have more complications from COVID-19 infections. The vulnerability levels of the different blocks of 1,102 municipal capitals were calculated. Additionally, the institutions that provide health services and hotels were georeferenced, and changes in people’s mobility dynamics in large cities were identified.
This research estimated the optimal size and composition of the portfolio, and its benefit–cost ratio, of COVID-19 vaccines that Colombia should negotiate as a price-taking country. The Advance Market Commitments (AMC) mathematical model was applied using the parameters from the Colombian context and from a literature review. The findings indicate that the optimal portfolio of Colombia should include 13 vaccines, mainly from two platforms: i) RNA and ii) inactivated virus. The benefit–cost ratio was always greater than one in the baseline scenario and after performing many sensitivity analyses on parameters such as the percentage of the population at risk, the price per treatment, and the herd immunity threshold, among others. In a context of high uncertainty, the best decision – with high benefit – is to anticipate the negotiation processes with the providers of COVID-19 vaccines, which will generate positive economic and health impacts.
Social protection systems are essential for mitigating poverty and income insecurity, particularly in developing countries where informal employment is pre
We developed an algorithm to explore unexpected growth in the usage and costs of health technologies. We exploit data from the expenditures on technologies funded by the Colombian government under the compulsory insurance system, where all prescriptions for technologies not included in an explicit list must be registered in a centralized information system, covering the period from 2017 to 2022. The algorithm consists of two steps: an outlier detection method based on the density of the expenditures for selecting a first set of technologies to consider (39 technologies out of 106,957), and two anomaly detection models for time series to determine which insurance companies, health providers, and regions have the most notorious increases. We have found that most medicines associated with atypical behavior and significant monetary growth could be linked to the use of recently introduced drugs in the market. These drugs have valid patents and very specific clinical indications, often involving high-cost pharmacological treatments. The most relevant case is the Burosumab, approved in 2018 to treat a rare genetic disorder affecting skeletal growth. Secondly, there is clear evidence of anomalous increasing trend evolutions in the identified enteral nutritional support supplements or Food for Special Medical Purposes. The health system did not purchase these products before July 2021, but in 2022 they represented more than 500,000 USD per month.
The uncertainty associated with the future of viruses such as SARS-CoV-2 poses a challenge to public health officials because of its implications for welfare, economics and population health. In this document, we develop an age-stratified epidemiological-mathematical model to predict various health outcomes, considering the effectiveness of COVID-19 vaccines. The analytical model proposed and developed for this research is based on the approach constructed by the COVID-19 International Modelling Consortium. Following this approach, this paper innovates at the frontier of knowledge by including the various variants of SARS-CoV-2 in the Consortium model. Furthermore, for the first time in international literature, a complete compilation of the formal mathematical development of this entire quantitative model is presented. Our model accurately fits the observed historical data of new infections, cumulative mortality, symptomatic infections, hospitalisations, and Intensive Care Units admissions, capturing the waves of contagion that have occurred in Bogotá, Colombia. In turn, the prognosis obtained indicates a considerable decrease in the incidence and lethality caused by SARS-CoV-2 under current conditions, thus evidencing the effectiveness of vaccines against infection, hospitalisation, and death. This model enables the evaluation of different scenarios in response to changes in the dynamics of this infectious disease, providing information to policymakers for real-world evidence-based decision-making.